The first patient underwent dosing in the phase 3 LUCIA clinical trial of Duravyu for wet age-related macular degeneration, according to a press release from EyePoint Pharmaceuticals.
The LUCIA trial comes on the heels of the phase 3 LUGANO trial, which began dosing in October. Both are aflibercept-controlled noninferiority trials to assess the safety and efficacy of Duravyu, a sustained-release intravitreal insert that delivers vorolanib, in patients with wet AMD, according to the release.
In each trial, approximately 400 patients will receive either a 2.7 mg dose of Duravyu or on-label